[Antirheumatic therapy with new non-steroidal compounds (author's transl)].

Non-steroidal antirheumatic agents have the same type of action qualitatively: they are more or less potent inhibitors of prostaglandin synthesis and also influence other mediators of the inflammatory process. Certain risks with these substances are the inevitable side-effects of their antiinflammatory/analgesic action. Experiments to improve this type of substance have, however, produced undoubted advances in longterm treatment with antirheumatic agents: the daily therapeutic doses could be markedly reduced, the dosage scheme became simpler and consequently compliance-orientated. With demonstrably effective tissue levels at the site of the inflammation they have a sustained action on the symptoms of rheumatic diseases.